| 時間 | 主題 | |||||
|---|---|---|---|---|---|---|
Renal cell carcinoma |
||||||
09:00 ~ 09:20 |
The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma in 2020
講者:
Christopher G. Wood
座長:
楊啟瑞, 張延驊 |
Christopher G. Wood |
楊啟瑞, 張延驊 |
|||
The rationale of sequencing in immunotherapy era for advanced renal cell carcinoma
講者:
Matthew T. Campbell
座長:
楊啟瑞, 張延驊 |
Matthew T. Campbell |
楊啟瑞, 張延驊 |
||||
Can we optimize 1st line systemic therapy selection base on genetic assessment?
講者:
Sumanta Kumar Pal
座長:
楊啟瑞, 張延驊 |
Sumanta Kumar Pal |
楊啟瑞, 張延驊 |
||||
Urothelial carcinoma |
||||||
Lynch syndrome in urologic patients: Relevance, diagnosis, screening, and management
講者:
Surena F. Matin
座長:
于大雄, 吳錫金, 林仁泰 |
Surena F. Matin |
于大雄, 吳錫金, 林仁泰 |
||||
The role of surgical consolidation in initially node positive muscle invasive bladder cancer
講者:
Neema Navai
座長:
于大雄, 吳錫金, 林仁泰 |
Neema Navai |
于大雄, 吳錫金, 林仁泰 |
||||
Emerging roles of perioperative therapy for muscle-invasive bladder cancer
講者:
蔡育賢
座長:
于大雄, 吳錫金, 林仁泰 |
蔡育賢 |
于大雄, 吳錫金, 林仁泰 |
||||
Prostate cancer |
||||||
Individualized treatment for metastatic prostate cancer
講者:
Brian F. Chapin
座長:
張兆祥, 查岱龍, 馮思中 |
Brian F. Chapin |
張兆祥, 查岱龍, 馮思中 |
||||
Third-line treatment for mCRPC
講者:
張延驊
座長:
張兆祥, 查岱龍, 馮思中 |
張延驊 |
張兆祥, 查岱龍, 馮思中 |
||||
11:40 ~ 12:00 |
Discussion
講者:
All
座長:
張兆祥, 查岱龍, 馮思中 |
All |
張兆祥, 查岱龍, 馮思中 |